Abstract
Medullary thyroid cancer (MTC) is a rare cancer. Vandetanib, a RET tyrosine-kinase inhibitor, significantly increased progression free survival and is the first treatment approved in France for unresectable, locally advanced or metastatic MTC that is symptomatic or progressive. Most frequents adverse events are diarrhea, folliculitis and asthenia. The prolongation of the QT interval on electrocardiogram is frequent but in the most of cases not clinically relevant. A good selection of the patients who could benefit from this treatment and management of side effect are important for the risk-benefit assessment.
Keywords:
medullary thyroid cancer; multiple endocrine neoplasia; targeted therapy; treatment; vandetanib.
Publication types
-
Research Support, Non-U.S. Gov't
-
Review
MeSH terms
-
Antineoplastic Agents / adverse effects
-
Antineoplastic Agents / therapeutic use*
-
Carcinoma, Medullary / drug therapy*
-
Carcinoma, Medullary / genetics
-
Carcinoma, Medullary / pathology
-
Carcinoma, Medullary / secondary
-
Carcinoma, Neuroendocrine
-
Humans
-
Piperidines / adverse effects
-
Piperidines / therapeutic use*
-
Proto-Oncogene Proteins c-ret / antagonists & inhibitors
-
Proto-Oncogene Proteins c-ret / genetics
-
Quinazolines / adverse effects
-
Quinazolines / therapeutic use*
-
Rare Diseases / drug therapy*
-
Rare Diseases / pathology
-
Thyroid Neoplasms / drug therapy*
-
Thyroid Neoplasms / genetics
-
Thyroid Neoplasms / pathology
Substances
-
Antineoplastic Agents
-
Piperidines
-
Quinazolines
-
Proto-Oncogene Proteins c-ret
-
vandetanib
Supplementary concepts
-
Thyroid cancer, medullary